FDA Approves Label Update For Biofrontera’s Ameluz Gel To Highlight Hypersensitivity Warnings
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208081s040lbl.pdf
The FDA approved updated warning labels for Biofrontera's skin medicine to tell doctors and patients about rare allergic reactions. When a company has to add safety warnings, watch to see if doctors still prescribe the medicine or if they choose other options instead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.